PET Study of Cerebral Metabolism of 11C-acetoacetate and 18F-FDG in Patients Under Moderate Ketosis

NCT ID: NCT02409784

Last Updated: 2019-02-15

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Regional brain glucose hypometabolism occurs during aging and may contribute to the onset of aging-related cognitive impairment in humans. Ketones are the main alternative energy substrate to glucose for the brain. Several studies show that brain ketone uptake and metabolism are unaltered in cognitively-normal older persons and in Alzheimer's disease (AD). Nutritional ketosis is reported to have a positive impact on cognitive performances in mild cognitive impairment and AD. Nevertheless, changes in regional brain glucose and ketone uptake in adults are poorly understood during diet-induced experimental ketosis. The investigators hypothesis was that during diet-induced ketosis, brain ketone uptake would be directly correlated with the elevation of blood ketone levels and inversely correlated to brain glucose uptake.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Ten participants received a very high fat ketogenic diet (KD) (4.5:1; lipid:protein plus carbohydrates) for four days.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ketogenic diet

Pre/Post TEP study with a 4 days ketogenic diet (KD).

Interventions 1: Pre-KD = Participants did a TEP before starting the 4-day diet

Intervention 2: Post-KD = Participants did a TEP after completing the 4-day diet

Group Type EXPERIMENTAL

Pre-KD

Intervention Type DIETARY_SUPPLEMENT

Before starting 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet

Post-KD

Intervention Type DIETARY_SUPPLEMENT

After 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pre-KD

Before starting 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet

Intervention Type DIETARY_SUPPLEMENT

Post-KD

After 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults
* No signs of cognitive impairment

Exclusion Criteria

* Not within the age limits
* Pregnancy or breast feeding
* Incapacity to withstand a supine position for 40 min
* Non lacunar infarction
* Known psychiatric history of schizophrenia, psychotic disorders, major affective disorders (bipolar disorder and major depression \<5 years), panic disorder, obsessive compulsive disorders and other conditions that may affect memory
* Epilepsy, brain trauma with loss of consciousness, subarachnoid hemorrhage
* History of alcool and/or substances abuse (excessive alcool consumption ≥10 drinks/weeks)
* Parkinson disease
* Down syndrome
* Inflammatory disease
* Abnormal blood pressure, liver or kidney function, blood count
* Dyslipidemia, hypothyroidism, osteoporosis
* Presence of a metal object in the body
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Université de Sherbrooke

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephen C Cunnane, PhD

Role: PRINCIPAL_INVESTIGATOR

Université de Sherbrooke

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

13-214

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Supplementing Neuro-Energy to Aid Cognition
NCT06767124 NOT_YET_RECRUITING NA
[18F]MC225-PET in Neurodegenerative Disease
NCT05853471 UNKNOWN PHASE1/PHASE2